We are live on ! Find out more

Danaher

DHR

Market cap $165B

234.93 USD

+4.82

2.09%

At close Updated Nov 4, 4:00 PM EST

Pre-market

After hours

235.00

+0.07

0.03%

1 day

2.09%

5 days

0.4%

1 month

6.2%

3 months

20.61%

6 months

34.99%

Year to date

1.97%

1 year

9.87%

5 years

-13.4%

10 years

244.42%

About: In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life sciences and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.

Employees: 60,000

Healthcare Diagnostics & Research

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 61.9%

Neutral 38.1%

Negative 0%

Danaher to Present at UBS Global and Jefferies Global Healthcare Conferences

WASHINGTON, Nov. 2, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Julie Sawyer Montgomery, will be presenting at the UBS Global Healthcare Conference in Palm Beach, Florida on Monday, November 9, 2026 at 11:45 a.m. ET and Jefferies Global Healthcare Conference in London, UK on November 17, 2026 at 10:00 a.m.

Danaher to Present at UBS Global and Jefferies Global Healthcare Conferences

Zacks Investment Research

Danaher (DHR) Upgraded to Buy: Here's Why

Danaher (DHR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Danaher (DHR) Upgraded to Buy: Here's Why

Zacks Investment Research

LH vs. DHR: Which Stock Is the Better Value Option?

Investors interested in Medical Services stocks are likely familiar with Labcorp Holdings (LH) and Danaher (DHR). But which of these two stocks is more attractive to value investors?

LH vs. DHR: Which Stock Is the Better Value Option?

Danaher Q3 Recap: Decent Results, Still A Hold

Danaher Corporation is rated hold, as the stock trades at a small premium and offers an 8.85% expected return, below my threshold. Q3 earnings showed solid performance: revenue up 8.3% YoY to $6.55B, adjusted EPS of $2.11, and strong segment growth, especially in Diagnostics. Key headwinds include respiratory revenue volatility and pricing pressure from China's volume-based procurement, despite some recent positive trends.

Danaher Q3 Recap: Decent Results, Still A Hold

The Motley Fool

Why Danaher Stock Bounced Higher Today

It beat analyst estimates for both revenue and profitability. Its full-year earnings guidance also topped the pundit consensus.

Why Danaher Stock Bounced Higher Today

Danaher Corporation (DHR) Q3 2026 Earnings Call Transcript

Danaher Corporation ( DHR ) Q3 2026 Earnings Call October 21, 2026 8:00 AM EDT Company Participants Rachel Vatnsdal Olson - Vice President of Investor Relations Julie Montgomery - President, CEO & Director Matthew Gugino - Executive VP & CFO Conference Call Participants Doug Schenkel Vijay Kumar - Evercore ISI Institutional Equities, Research Division Tycho Peterson - Jefferies LLC, Research Division Jack Meehan - Operon Research, LLC Scott Davis - Melius Research LLC Casey Woodring - JPMorgan Chase & Co, Research Division Elizabeth Koslosky - Goldman Sachs Group, Inc., Research Division Presentation Operator My name is Chelsea, and I will be your conference facilitator this morning. At this time, I would like to welcome everyone to Danaher Corporation's Third Quarter 2026 Earnings Results Conference Call.

Danaher Corporation (DHR) Q3 2026 Earnings Call Transcript

The Motley Fool

Danaher: 3 Key Takeaways for Long-Term Investors

Danaher raised full-year earnings per share guidance to $8.57 to $8.62. Biotechnology orders grew mid-teens during the third quarter.

Danaher: 3 Key Takeaways for Long-Term Investors

Danaher Q3 Review: Interested To See What The New Management Will Bring

Danaher Corporation delivered mixed Q3 results, with revenue up 8.3% y/y but growth driven mainly by acquisitions and tariff refunds. Adjusted operating margin reached 29%, exceeding guidance, yet organic growth and profitability improvements remain modest and partly non-recurring. Management's Q4 guidance implies lower-than-expected EPS, and the new CEO signals a need for stronger growth and operational execution.

Danaher Q3 Review: Interested To See What The New Management Will Bring

Zacks Investment Research

DHR Q3 Earnings Beat on Biotechnology Strength, Sales in Line

Danaher's third-quarter earnings beat estimates by 9.9%, driven by stronger Biotechnology profitability, while it raised its 2026 adjusted earnings outlook.

DHR Q3 Earnings Beat on Biotechnology Strength, Sales in Line

Danaher Beats Profit Estimates, Raises Outlook as Customer Demand Improves

Danaher Corp. (NYSE:DHR) on Wednesday reported third-quarter adjusted earnings of $2.11 per share, beating the analyst consensus estimate of $1.92.

Danaher Beats Profit Estimates, Raises Outlook as Customer Demand Improves

See News Rankings

Price charts implemented using Lightweight Charts™